Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Koichi Fujiu is active.

Publication


Featured researches published by Koichi Fujiu.


The Annals of Thoracic Surgery | 2002

Chyothorax associated with massive osteolysis (Gorham’s syndrome)

Koichi Fujiu; Ryuzo Kanno; Hiroyuki Suzuki; Naoya Nakamura; Mitsukazu Gotoh

We report a 15-year-old boy with bilateral chylothorax complicating Gorhams syndrome. Thoracic duct ligation failed to prevent fluid reaccumulation. The patient died of lymphocytopenia. Autopsy revealed vascular proliferation in the parietal and visceral pleura as well as in the ribs, which seemed to cause persistent chylothorax responsible for the poor prognosis of this patient. We reviewed treatments provided to 22 patients reported in the literature with Gorhams syndrome and chylothorax.


The Japanese Journal of Thoracic and Cardiovascular Surgery | 2002

Endoscopic closure of bronchopleural fistula after pneumonectomy by submucosal injection of polidocanol

Ryuzo Kanno; Hiroyuki Suzuki; Koichi Fujiu; Akio Ohishi; Mitsukazu Gotoh

We report two cases of a bronchopleural fistula with, and without, empyema treated by endoscopic submucosal injection of polidocanol (sclerotherapy) and application of cyanoacrylate. Case 1: A 60-year-old man underwent left pleuropneumonectomy for lung cancer. He developed bronchopleural fistula with empyema at 32 days after the operation. We performed sclerotherapy around the fistula. The air leakage stopped at 2 weeks after the sclerotherapy, and the fistula was closed. He was eventually cured of the empyema by pleural drainage. Case 2: A 61-year-old man underwent left pneumonectomy for lung cancer. He developed bronchopleural fistula without empyema at 50 days after the operation. We performed sclerotherapy and application of cyanoacrylate. After this therapy, the air leakage stopped immediately, and the bronchopleural fistula was closed. The sclerotherapy and application of cyanoacrylate are not only technically easy, but also very effective for treatment of bronchopleural fistula. Sclerotherapy and cyanoacrylate may be advocated as a first therapeutic step.


Cancer Letters | 2002

Expression of peanut agglutinin-binding carbohydrates correlates with nodal involvement in human lung adenocarcinoma.

Hiroyuki Suzuki; Takanori Kawaguchi; Mitsunori Higuchi; Yutaka Shio; Koichi Fujiu; Ryuzo Kanno; Akio Ohishi; Ryoichi Motoki; Mitsukazu Gotoh

The expression of 15 kinds of lectin-binding carbohydrates was examined histochemically in lung adenocarcinoma. The relation between expression of lectin binding carbohydrates and clinicopathologic factors was studied. The expression of peanut agglutinin (PNA) binding carbohydrates showed a high lymph node metastatic rate. Relation between PNA-binding carbohydrate expression and lymphatic vessel invasion was also recognized. Multivariate analysis showed that PNA-binding carbohydrate expression was an independent predictive factor of lymph node metastasis (odds ratio: 2.8) and of lymphatic vessel invasion (odds ratio: 5.2). The expression of PNA-binding carbohydrates would be a significant predictive factor for lymph node metastasis of lung adenocarcinomas.


The Japanese Journal of Thoracic and Cardiovascular Surgery | 2010

Immunoglobulin G4-related inflammatory pseudotumor of the lung.

Koichi Fujiu; Hideo Sakuma; Hideaki Miyamoto; Bunpei Yamaguchi

An 82-year-old man presented with a nodule in the right S2a of the lung as seen by chest computed tomography (CT). He had undergone treatment for chronic obstructive lung disease. He had a 53-year history of smoking 20 cigarettes a day. Subsequent to the appearance of the nodule in the right S2a, the CT images revealed consolidations in the right S2b, right S3, and left S5. The nodule in the right S2a was diagnosed as squamous cell carcinoma after performing video-assisted thoracoscopic wedge resection of the lung. After 4 months, the size of the consolidation in the right S2b increased. Recurrence of lung cancer was suspected. Using transbronchial lung biopsy, the consolidation in the left S5 was diagnosed as organizing pneumonia; therefore, right upper lobectomy was performed. The consolidations in the right S2b and right S3 were diagnosed as inflammatory pseudotumors with infiltrations of immunoglobulin G4-positive plasma cells.


Internal Medicine | 2016

Bronchoscopic Investigation of Atypical Drug-induced Hypersensitivity Syndrome Showing Viral Lung Involvement.

Isano Hase; Hiroaki Arakawa; Hideo Sakuma; Fumio Kaneko; Yuzuru Watanabe; Koichi Fujiu; Hideaki Miyamoto; Yoshiki Ishii

We herein report a case of atypical drug-induced hypersensitivity syndrome (DIHS) involving serological reactivation of cytomegalovirus induced by carbamazepine with pulmonary and skin manifestations. These lesions were not present on admission, but developed on virus reactivation as indicated by the presence of inclusion bodies and multinucleated giant cells in alveolar cells with CD8(+) T lymphocyte infiltration on a transbronchial lung biopsy. Although the precise mechanism of DIHS remains unknown, this case suggests the crucial role of viral reactivation in pulmonary lesions in DIHS.


Oncology Letters | 2017

Efficacy and tolerability of nanoparticle albumin-bound paclitaxel in combination with carboplatin as a late-phase chemotherapy for recurrent and advanced non-small-cell lung cancer: A multi-center study of the Fukushima lung cancer association group of surgeons

Mitsunori Higuchi; Hironori Takagi; Yuki Owada; Takuya Inoue; Yuzuru Watanabe; Takumi Yamaura; Mitsuro Fukuhara; Satoshi Muto; Naoyuki Okabe; Yuki Matsumura; Takeo Hasegawa; Atsushi Yonechi; Jun Osugi; Mika Hoshino; Yutaka Shio; Koichi Fujiu; Ryuzo Kanno; Akio Ohishi; Hiroyuki Suzuki; Mitsukazu Gotoh

The present retrospective multi-center study aimed to evaluate the efficacy and feasibility of nanoparticle albumin-bound (nab)-paclitaxel plus carboplatin as a second or late-phase chemotherapy in patients with non-small cell lung cancer (NSCLC). A total of 25 patients with recurrent or advanced NSCLC who had received previous chemotherapy were treated with nab-paclitaxel (70-100 mg/m2, intravenously) on days 1, 8 and 15 every 28 days with a carboplatin area under the concentration-time curve of 4-6 on day 1. The overall response rate, disease control rate, progression-free survival (PFS), overall survival (OS) and toxicities were statistically evaluated. Of the 25 patients, there were 9 cases of recurrent disease following surgery, 16 cases of advanced disease, 13 cases of adenocarcinoma, 11 cases of squamous cell carcinoma and 1 case of large cell carcinoma. A total of 13 patients received second-line chemotherapy and 12 received fourth-line or later chemotherapy. One patient exhibited a complete response, 7 had a partial response, 10 exhibited stable disease and 7 had progressive disease. The overall response rate was 32.0% and the disease control rate was 72.0%. The median PFS and median OS following nab-paclitaxel treatment were 4.0 and 14.0 months, respectively. Frequent treatment-associated adverse events were myelosuppression, peripheral neuropathy, gastrointestinal symptoms and baldness, the majority of which were grade 1-2. Grade 3-4 neutropenia, thrombocytopenia and anemia occurred in 7 (28.0%), 3 (12.0%) and 2 (8.0%) patients, respectively. No patients experienced grade 3-4 sensory neuropathy and no grade 5 adverse effects were observed. Nab-paclitaxel plus carboplatin as second-phase or later chemotherapy provided a small but significant survival benefit for patients with recurrent or advanced NSCLC, with tolerable adverse effects. To the best of our knowledge, the results of the present study demonstrated for the first time that nab-paclitaxel plus carboplatin is a promising and feasible late-phase chemotherapeutic agent for NSCLC.


The Japanese Journal of Thoracic and Cardiovascular Surgery | 2009

Solitary fibrous tumors of the pleura presenting satellite tumors

Koichi Fujiu; Hideaki Miyamoto; Hideo Sakuma; Masatoshi Mori

A 29-year-old man presented with a mass in the left lower lung field on a chest radiograph obtained during a medical checkup. Computed tomography revealed a tumor adjacent to the diaphragm. A sessile tumor measuring 10.5 × 8.5 × 4.5 cm arising from the parietal pleura was resected. The tumor was accompanied by several little tumors on the nearby diaphragm. Pathologically, the major tumor consisted of typical spindle-shaped cells with myxoid degeneration. There was no increased cellularity, cellular pleomorphism, or a high mitotic count. In immunohistochemical studies, the spindle cells showed positive staining for CD34 and were negative for bcl-2. The smaller tumors also consisted of myxoid degeneration. We diagnosed benign solitary fibrous tumor of the pleura with satellite tumors. We must be aware of the possibility of satellite tumors when we treat patients with a benign solitary fibrous tumor.


Clinical Cancer Research | 2006

Identification of the Decay-Accelerating Factor CD55 as a Peanut Agglutinin–Binding Protein and Its Alteration in Non–Small Cell Lung Cancers

Mitsunori Higuchi; Yuichi Endo; Hiroyuki Suzuki; Fumihiko Osuka; Yutaka Shio; Koichi Fujiu; Ryuzo Kanno; Akio Oishi; Teizo Fujita; Mitsukazu Gotoh

Purpose: Peanut agglutinin (PNA) recognizes tumor-associated carbohydrates. In this study, we aimed to identify the core protein harboring PNA-binding sugars in the human lung and to explore the relationship with the pathology of primary non–small cell lung cancers (NSCLC). Experimental Design: PNA lectin blotting was used to detect PNA-binding proteins in the microsomal fraction of lung tissue from 24 patients with NSCLC. The 55- to 65-kDa core peptide PNA-binding protein was characterized by enzymatic treatment and identified by immunoprecipitation and affinity chromatography. The expression level and increase in size of the 55- to 65-kDa PNA-binding protein/decay-accelerating factor (DAF) were compared between normal and tumor regions of the tumor tissue by Western blotting and quantitative PCR. Results: The 55- to 65-kDa PNA-binding protein was observed in human lung. This was a glycosylphosphatidylinositol-anchored membrane protein carrying O-linked carbohydrates. This core protein was identified as DAF, one of the complementary regulatory proteins. DAF was enlarged to 65 to 75 kDa in NSCLC tumor lesions due to sialylation in the sugar moiety. At the transcription level, DAF levels were significantly lower in tumor regions, suggesting its down-regulation in NSCLC cells. Conclusions: DAF was identified as a new PNA-binding protein in the human lung. The down-regulation and heavy sialylation of DAF was associated with pathology in NSCLC, and these alterations make this protein a potential marker for NSCLC.


Internal Medicine | 2017

Pirfenidone-induced Eosinophilic Pleurisy

Isano Hase; Bunpei Yamaguchi; Hidenori Takizawa; Hiroaki Arakawa; Hideo Sakuma; Koichi Fujiu; Hideaki Miyamoto; Yoshiki Ishii

The patient was a 69-year-old man with idiopathic pulmonary fibrosis who was taking pirfenidone. After 7 weeks of treatment, he suffered from left-sided eosinophilic pleurisy. Medical thoracoscopy was performed and the histopathological examination of the parietal pleura revealed the massive infiltration of eosinophils and lymphoid follicles. After stopping pirfenidone therapy, the patients pleural effusion disappeared without additional treatment, and never recurred. This is the first case report of pirfenidone-induced pleurisy.


The Annals of Thoracic Surgery | 2003

Hemopneumothorax associated with Marfan syndrome and congenital afibrinogenemia

Ryuzo Kanno; Hiroyuki Suzuki; Koichi Fujiu; Yasuaki Yoshino; Akio Ohishi; Mitsukazu Gotoh

In patients with afibrinogenemia who require operation, prophylaxis against bleeding is important. We report the case of a 14-year-old boy with Marfan syndrome and congenital afibrinogenemia in whom hemopneumothorax developed. Video-assisted thoracoscopic surgery was performed successfully under intravenous administration of fibrinogen and with careful monitoring of plasma fibrinogen level.

Collaboration


Dive into the Koichi Fujiu's collaboration.

Top Co-Authors

Avatar

Hiroyuki Suzuki

Fukushima Medical University

View shared research outputs
Top Co-Authors

Avatar

Ryuzo Kanno

Fukushima Medical University

View shared research outputs
Top Co-Authors

Avatar

Mitsukazu Gotoh

Fukushima Medical University

View shared research outputs
Top Co-Authors

Avatar

Yutaka Shio

Fukushima Medical University

View shared research outputs
Top Co-Authors

Avatar

Mitsunori Higuchi

Fukushima Medical University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jun Ohsugi

Fukushima Medical University

View shared research outputs
Top Co-Authors

Avatar

Takanori Kawaguchi

Fukushima Medical University

View shared research outputs
Top Co-Authors

Avatar

Akio Oishi

Fukushima Medical University

View shared research outputs
Top Co-Authors

Avatar

Atsushi Yonechi

Fukushima Medical University

View shared research outputs
Researchain Logo
Decentralizing Knowledge